Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Xenon ( (XENE) ) has issued an update.
Xenon Pharmaceuticals will showcase new Phase 3 and long-term data for its lead candidate azetukalner in focal onset seizures at the 2026 American Academy of Neurology meeting in Chicago. The company’s presentations span late-breaking topline X-TOLE2 results, 48‑month extension data, and real-world evidence on the burden of antiseizure medication titration and the need for no-titration options in epilepsy.
Additional AAN presentations will address the impact of comorbid depression on healthcare utilization and outcomes in newly diagnosed epilepsy patients, as well as preclinical results from Xenon’s NaV1.1 program in Dravet syndrome. The breadth of data is set to underscore Xenon’s positioning in epilepsy and broader neurology, highlighting both near-term clinical readouts for azetukalner and the potential of its early-stage pipeline.
The most recent analyst rating on (XENE) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
The score is held back primarily by weak financial performance—large net losses and substantial ongoing cash burn—despite a relatively strong, low-debt balance sheet that has been further reinforced by recent equity financing. Technicals are a meaningful positive, with the stock trending above key moving averages and positive momentum. Valuation is constrained by negative earnings and no indicated dividend yield.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development and commercialization of therapeutics for neurological and psychiatric conditions. Its lead drug candidate, azetukalner, a selective KV7 potassium channel opener, is in Phase 3 trials for epilepsy, major depressive disorder and bipolar depression, alongside early-stage potassium and sodium channel modulators for pain.
Average Trading Volume: 1,419,773
Technical Sentiment Signal: Buy
Current Market Cap: $5.42B
Find detailed analytics on XENE stock on TipRanks’ Stock Analysis page.